---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-119941"
form_type: "8-K"
ticker: "CLRB"
cik: "0001279704"
company_name: "Cellectar Biosciences, Inc."
filed_at: "2024-11-18T23:59:59+00:00"
generated_at: "2026-05-29T22:54:59.993578+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Cellectar Q3 cash $34.3M; raised $19.4M with potential $73.3M; positive WM data supports NDA

## Summary
- Cash $34.3M at Sept 30, 2024, up from $9.6M at Dec 31, 2023; raised $19.4M from warrant exercises with potential for additional $73.3M.
- Q3 R&D expenses $5.5M (down from $7.0M YoY) due to end of WM pivotal enrollment; G&A $7.8M (up from $2.4M YoY) for commercialization prep.
- Positive Phase 2 CLOVER-WaM results for iopofosine I 131 in WM; planning near-term NDA submission for accelerated approval.
- Data selected for oral presentation at ASH meeting on Dec 9, 2024.
- Entered supply agreements (SpectronRx, Northstar) and collaboration with City of Hope for mycosis fungoides.

## SEC filing metadata
- accession: 0001104659-24-119941
- form_type: 8-K
- ticker: CLRB
- cik: 0001279704
- company_name: Cellectar Biosciences, Inc.
- filed_at: 2024-11-18T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1279704/000110465924119941/0001104659-24-119941-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1279704/000110465924119941/tm2428692d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-119941
- JSON: https://secwatch.observer/filing/0001104659-24-119941.json
- Plain text: https://secwatch.observer/filing/0001104659-24-119941.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.